BIO Asia-Taiwan 2022 wraps up, marking another successful edition of the region’s largest bioindustry-focused conference and expo

Visitors to the show exceed 100,000 people over 4 days

The success of BIO Asia-Taiwan testifies to Taiwan booming biotech industry

TAIPEI, August 8, 2022 /PRNewswire/ — BIO Asia–Taiwan 2022, held at TaiNEX 2 Exhibition Center, Nangang, taipeifrom July 27 to 31, successfully concluded on Sunday 31st of July. Held in an innovative on-site and online format to encourage international participation, with the end of the pandemic, crowds returned to the event in large numbers; around 1,500 people from 30 countries attended the conference and other on-site events while more than 100,000 people visited the exhibition. With Taiwan The biomedical sector continues to grow strongly, the recent success of BIO Asia-Taiwan testifies to this growth. True to its theme “Connecting the Asian Value Chain”, the event provided the perfect platform for the global biotech community to connect with Asian value and supply chains.

Commenting on the importance of the gathering, Wallace Lin, Secretary General of the Taiwan Bio-Industry Organization (Taiwan BIO) said that as biotechnology is a global industry, the market, regulations and products must comply with international standards and be aligned with international requirements. “BIO Asia–Taiwan not only provides the platform for Taiwan to engage with the global biomedical community to help meet these demands, but also allows the world to see Taiwan. We aim to cement Taiwan as an essential player in the international value chain,” Lin said.

Lin also thanked PwC Taiwan, Taiwania Capital, Development Center for Biotechnology (DCB), Industrial Technology Research Institute (ITRI), Ministry of Health and Welfare, Academia Sinica, Taipei Medical University, EirGenix, Formosa Laboratories, Quanta Computer, Taiwan Digital Health Industry Development Association, and Precision Medicine Industry Association of Taiwan, as co-organizers of the conference. More than 100 local and foreign experts spoke in 22 sessions focusing on topics including post-pandemic strategy, advanced therapies, digital health, supply chain considerations, investment and regional cooperation.

One of the highlights of BIO Asia-Taiwan is the company presentation program, which this year includes 88 presentations from local and overseas biotechnology, pharmaceutical, materials, devices and diagnostics companies. Participating companies had the opportunity to engage with the on-site and online audience of potential investors and collaborators.

With the number of visitors reaching 100,000, the BIO Asia-Taiwan 2022 Expo showcased the latest achievements from industry, universities and research institutes. Fully booked with 1,500 booths from 15 participating countries, the four-day expo showcased 550 bio-industry manufacturers, including more than 50 listed companies, showing the pulse and achievements of the industry.

Foreign exhibitors interviewed expressed their enthusiasm for the opportunities offered by participating in BIO Asia-Taiwan 2022. Several mentioned that the event was also the perfect opportunity to Taiwan be exposed to innovative medical technologies from abroad.

BIO Asia–Taiwan providing the ideal platform for fundraising and exposure, the start-ups mentioned that they received significant attention and inquiries during the event.

This year, the exhibition featured a CDMO (Contract Development and Manufacturing Organization) area. In addition to an international zone, other special zones focusing on biosimilars, cell therapy and regenerative medicine, precision medicine and genetic testing, medical materials, services, smart medicine, equipment and instruments from the pharmaceutical industry, government entities, academic and research institutes and industry – highlights of academic collaboration.

The CDMO area included some of the Taiwan leading companies in this industrial space; Formosa Laboratories, EirGenix, Mycenax Biotech, Level Biotechnology, ScinoPharm, TFBS Bioscience, Amaran Biotech, Genovior Biotech, United BioPharma, Anne-Tong, etc. Topics presented included cell lines, biopharmaceutical drug development, clinical trials, and API production processes.

In the regenerative medicine area, products and equipment shared the stage, including the latest automated cell therapy systems, exosome particle size analyzers, and more.

Government research and promotion entities featured included Academia Sinica, Ministry of Health and Welfare, National Institutes of Health Research, Institute of Nuclear Energy Research, Center for Development of biotechnology (DCB) and biotechnology and biotechnology of the Ministry of Economic Affairs. and Pharmaceutical Industries Promotion Office (BPIPO).

This year, the National Science and Technology Council led Hsinchu Science Park, Central Taiwan Science Park, Southern Taiwan Science Park, Taiwan Instrument Research Institute and 36 other players industry to showcase innovations in new drugs, medical materials, telemedicine, medical cosmetics and zero-carbon businesses. The Research Center for the Science of Epidemic Prevention also presented an exhibition, while 13 research teams presented some of the Taiwan the most promising technologies ready to be licensed at the BioMed Commercialization Center.

In the international zone, 10 countries were presented; the UNITED STATESUK, Canada, Poland, Swiss, Australia, Malaysia, The Philippines, Belgium and Italy.

The Organizing Committee of BIO Asia-Taiwan said it has already entered into discussions with the event’s co-organizers, the World Biotechnology Innovation Organization (BIO) to organize BIO Asia-Taiwan 2023. With the release of Taiwan border restrictions looming, an increased number of international visitors are expected to attend next year’s event, leading to even greater business opportunities for everyone involved!

Previous Mitsui Sumitomo Announces $400M Cross-Cutting Acquisition
Next Massage Chair Market 2022-2028: Need for Relaxation, Stress Relief and Consumer Awareness of Therapeutic Benefits